A new mechanism of trastuzumab resistance in gastric cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathway

Anticancer strategies based on the metabolic profile of tumor cells: therapeutic targeting of the Warburg effect

(2016) Xi-sha Chen et al.   ACTA PHARMACOLOGICA SINICA

The Warburg effect and drug resistance

(2016) Bhaskar Bhattacharya et al.   BRITISH JOURNAL OF PHARMACOLOGY

Elevated Orai1 and STIM1 expressions upregulate MACC1 expression to promote tumor cell proliferation, metabolism, migration, and invasion in human gastric cancer

(2016) Jianling Xia et al.   CANCER LETTERS

Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer

(2016) Callie R. Merry et al.   Oncotarget

Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer

(2015) Amir Sonnenblick et al.   BMC Medicine

MACC1 Suppresses Cell Apoptosis in Hepatocellular Carcinoma by Targeting the HGF/c-MET/AKT Pathway

(2015) Yingmin Yao et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Lactate dehydrogenase inhibitors sensitize lymphoma cells to cisplatin without enhancing the drug effects on immortalized normal lymphocytes

(2015) Marcella Manerba et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Metastasis-Associated in Colon Cancer-1 Associates With Poor Prognosis and Promotes Cell Invasion and Angiogenesis in Human Cervical Cancer

(2015) Xiang Zhou et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer

(2015) Ji-Won Kim et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

EB-virus latent membrane protein 1 potentiates the stemness of nasopharyngeal carcinoma via preferential activation of PI3K/AKT pathway by a positive feedback loop

(2015) C-F Yang et al.   ONCOGENE

FoxM1 promotes breast tumorigenesis by activating PDGF-A and forming a positive feedback loop with the PDGF/AKT signaling pathway

(2015) Guanzhen Yu et al.   Oncotarget

AMPK-mediated energy homeostasis and associated metabolic effects on cancer cell response and resistance to cetuximab

(2015) Xinqun Li et al.   Oncotarget

MiR-338-3p inhibits epithelial-mesenchymal transition in gastric cancer cells by targeting ZEB2 and MACC1/Met/Akt signaling

(2015) Na Huang et al.   Oncotarget

Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance

(2015) Qiang Zuo et al.   Scientific Reports

A positive feedback loop involving Erk5 and Akt turns on mesangial cell proliferation in response to PDGF

(2014) Amit Bera et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies

(2014) D Tural et al.   BRITISH JOURNAL OF CANCER

HER2 Expression and PI3K-Akt Pathway Alterations in Gastric Cancer

(2014) Yasutaka Sukawa et al.   DIGESTION

The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey

(2014) Giuseppe Aprile et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

(2014) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

MACC1 supports human gastric cancer growth under metabolic stress by enhancing the Warburg effect

(2014) L Lin et al.   ONCOGENE

Autophagy promotes paclitaxel resistance of cervical cancer cells: involvement of Warburg effect activated hypoxia-induced factor 1-α-mediated signaling

(2014) X Peng et al.   Cell Death & Disease

Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

(2014) T. J. Parmenter et al.   Cancer Discovery

Expression of MACC1 and c-Met in human gastric cancer and its clinical significance

(2013) Tiankang Guo et al.   Cancer Cell International

Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines

(2013) Yukiko Oshima et al.   Gastric Cancer

Metastasis-associated in colon cancer-1 upregulation predicts a poor prognosis of gastric cancer, and promotes tumor cell proliferation and invasion

(2013) Lin Wang et al.   INTERNATIONAL JOURNAL OF CANCER

Metabolic targets for cancer therapy

(2013) Lorenzo Galluzzi et al.   NATURE REVIEWS DRUG DISCOVERY

Testican-1-mediated epithelial–mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer

(2013) H-P Kim et al.   ONCOGENE

Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma

(2012) Y-C Shen et al.   BRITISH JOURNAL OF CANCER

Increased signalling of EGFR and IGF1R and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas

(2012) A Gallardo et al.   BRITISH JOURNAL OF CANCER

A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors

(2012) Luis E. Raez et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Mechanism of resistance to trastuzumab and molecular sensitization via ADCC activation by exogenous expression of HER2-extracellular domain in human cancer cells

(2012) Ryosuke Yoshida et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

KRas Induces a Src/PEAK1/ErbB2 Kinase Amplification Loop That Drives Metastatic Growth and Therapy Resistance in Pancreatic Cancer

(2012) J. A. Kelber et al.   CANCER RESEARCH

Modulation of Glucose Metabolism by CD44 Contributes to Antioxidant Status and Drug Resistance in Cancer Cells

(2012) M. Tamada et al.   CANCER RESEARCH

The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and Tumorigenesis

(2012) Chia-Hsin Chan et al.   CELL

The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer

(2012) B. M. Slomovitz et al.   CLINICAL CANCER RESEARCH

Multiple Biological Activities of Lactic Acid in Cancer: Influences on Tumor Growth,Angiogenesis and Metastasis

(2012) Suveera Dhup et al.   CURRENT PHARMACEUTICAL DESIGN

Overcoming Trastuzumab Resistance in Breast Cancer by Targeting Dysregulated Glucose Metabolism

(2011) Y. Zhao et al.   CANCER RESEARCH

Effects of metastasis-associated in colon cancer 1 inhibition by small hairpin RNA on ovarian carcinoma OVCAR-3 cells

(2011) Ruitao Zhang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+breast cancer patients

(2011) Maurizio Scaltriti et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib

(2010) Giorgio Valabrega et al.   BREAST CANCER RESEARCH AND TREATMENT

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Trastuzumab in gastric cancer

(2010) Alicia F.C. Okines et al.   EUROPEAN JOURNAL OF CANCER

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines

(2009) Y. Kataoka et al.   ANNALS OF ONCOLOGY

Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug

(2009) J. Guillermet-Guibert et al.   MOLECULAR CANCER THERAPEUTICS

MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis

(2008) Ulrike Stein et al.   NATURE MEDICINE